TY - JOUR
T1 - Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy
AU - Takata, Akihiro
AU - Takiguchi, Shuji
AU - Miyazaki, Yasuhiro
AU - Miyata, Hiroshi
AU - Takahashi, Tsuyoshi
AU - Kurokawa, Yukinori
AU - Yamasaki, Makoto
AU - Nakajima, Kiyokazu
AU - Mori, Masaki
AU - Kangawa, Kenji
AU - Doki, Yuichiro
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc.
PY - 2015/8/30
Y1 - 2015/8/30
N2 - Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.
AB - Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.
UR - http://www.scopus.com/inward/record.url?scp=84938290876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938290876&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000000986
DO - 10.1097/SLA.0000000000000986
M3 - Article
C2 - 25361222
AN - SCOPUS:84938290876
VL - 262
SP - 230
EP - 236
JO - Annals of Surgery
JF - Annals of Surgery
SN - 0003-4932
IS - 2
ER -